Kelly Doyle
No Rating Available
(Learn About Our Rating System)

Kelly Doyle, PhD, DABCC, FAACC

Languages spoken: English, Portuguese, Spanish

  • Dr. Kelly Doyle is a fellow in the National Academy of Clinical Biochemistry and is a board certified clinical chemist. His interests involve the clinical application and implementation of mass spectrometry, emerging biomarkers, toxicology, endocrinology, and laboratory best practice. He has a special interest in training clinical chemistry fellows and teaching principles of laboratory medicine to pathology residents and medical students.

    Specialties

    • Pathology, Clinical

    Board Certification

    American Board of Clinical Chemistry

  • Dr. Kelly Doyle is a fellow in the National Academy of Clinical Biochemistry and is a board certified clinical chemist. His interests involve the clinical application and implementation of mass spectrometry, emerging biomarkers, toxicology, endocrinology, and laboratory best practice. He has a special interest in training clinical chemistry fellows and teaching principles of laboratory medicine to pathology residents and medical students.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary
    Board Certification
    American Board of Clinical Chemistry

    Education history

    Fellowship Clinical Chemistry - University of Utah School of Medicine Fellow
    Oncology and Medicinal Chemistry - Huntsman Cancer Institute, Center for Investigational Therapeutics Postdoctoral Research Fellow
    Doctoral Training Medicinal Chemistry - University of Utah Ph.D.
    Chemistry - Utah State University B.S.

    Selected Publications

    Journal Article

    1. Ammer T, Schutzenmeister A, Rank CM, Doyle K (2023). Estimation of Reference Intervals from Routine Data Using the refineR Algorithm – A Practical Guide. J Appl Lab Med, 8(1), 84-91.
    2. Erickson JA, Chiang FI, Walker CM, Genzen JR, Doyle K (2022). Comparison of two chromogranin A assays and investigation of nonlinear specimens. Pract Lab Med, 32, e00299.
    3. Nelson HA, Laulu S, Lu J, Doyle K (2022). Mitigation of Biotin Interference in Manual and Automated Immunoassays by Pre-Conjugating Biotinylated Antibodies to the Streptavidin Surface as an Alternative to Biotin Depletion. J Appl Lab Med, 7(3), 762-775.
    4. Doyle K, Frank EL (2021). Verifying Clinically Derived Reference Intervals for Daily Excretion Rates of Fractionated Metanephrines Using Modern Indirect Reference Interval Models. Am J Clin Pathol, 156(4), 691-699.
    5. Kroner GM, Johnson-Davis KL, Doyle K, McMillin GA (2019). Cannabinol (CBN) Cross-Reacts with Two Urine Immunoassays Designed to Detect Tetrahydrocannabinol (THC) Metabolite. J Appl Lab Med, 5(3), 569-574. (Read full article)
    6. cAlthaus, T, Lubell, Y, Maro, V P, Mmbaga, B T, Lwezaula, B, Halleux, C, Biggs, H M, Galloway, R L, Stoddard, R A, Perniciaro, J L, Nicholson, W L, Doyle K, Olliaro, P, Crump, J A, Rubach, M P (2020). Sensitivity of C-reactive Protein for the Identification of Patients with Laboratory-Confirmed Bacterial Infections in Northern Tanzania. Trop Med Int Health, 25(3), 291 - 300.
    7. Bahr TM, Christensen RD, Ward DM, Meng F, Jackson LK, Doyle K, Christensen DR, Harvey AG, Yaish HM (2019). Ferritin in serum and urine: A pilot study. Blood Cells Mol Dis, 76, 59-62. (Read full article)
    8. Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma S (2018). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924. (Read full article)
    9. Natali R, Wand C, Doyle K, Noguez JH (2018). Evaluation of a new venous catheter blood draw device and its impact on specimen hemolysis rates. Pract Lab Med, 10, 38-43. (Read full article)
    10. Doyle K, Strathmann FG (2017). Cost and Efficacy Assessment of an Alternative Medication Compliance Urine Drug Testing Strategy. Pain Med, 18(2), 307-315. (Read full article)
    11. Marin SJ, Doyle K, Chang A, Concheiro-Guisan M, Huestis MA, Johnson-Davis KL (2016). One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry. J Anal Toxicol, 40(1), 37-42. (Read full article)
    12. Doyle K, Fitzpatrick FA (2010). Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J Biol Chem, 285(23), 17417-24. (Read full article)
    13. Cordray P, Doyle K, Edes K, Moos PJ, Fitzpatrick FA (2007). Oxidation of 2-Cys-peroxiredoxins by arachidonic acid peroxide metabolites of lipoxygenases and cyclooxygenase-2. J Biol Chem, 282(45), 32623-9. (Read full article)

    Review

    1. Doyle K, Bunch DR (2023). Reference Intervals: Past, Present, and Future. [Review]. Crit Rev Clin Lab Sci.
    2. Kushnir MM, Nelson HA, Doyle K (2022). Clinical Utility and Analytical Aspects of Direct Measurements of Free Hormones Using Mass Spectrometry Based Methods. [Review]. J Appl Lab Med, 7(4), 945-970.
    3. Johnson-Davis KL, Doyle K (2019). Therapeutic Drug Monitoring in Pregnant Patients. [Review]. Ther Drug Monit, 42(2), 172-180. (Read full article)

    Commentary

    1. Doyle K (2021). Commentary on Extreme Hyperglycemia in an Elderly Patient. Clin Chem, 67(5), 729.

    Case Report

    1. Mathewson NJ, Pearson LN, Doyle K (2023). Abnormal HbA1c Result from a Diabetic Patient Leads to Unexpected Diagnosis. Clinical Chemistry (Chicago), 69(7), 684-689.

    Other

    1. Doyle K (2018). Parkin Function in Parkinson’s Disease. Clin Chem (64(11), p. 1676).

    Patent

    1. Hariprasad VM, Bearss D, Mollard A, Doyle K, Currie S, Sharma S, Graves B (2012). Substituted 1H-Pyrazolo-Pyrimidin and Pyridine Series of ETS Family Transcription Factor Inhibiting Compounds.